Science & Enterprise subscription

Follow us on Twitter

  • New post on Science and Enterprise: Editorial Posts Resume Tomorrow https://t.co/ZTVMsYlwg8 #Science #Business
    about 6 hours ago
  • As mobile phones, smart watches, and tablets play an increasingly key role in our daily lives, a new report shows m… https://t.co/HNOl3qa4oI
    about 2 days ago
  • New post on Science and Enterprise: Infographic – Mobile Industry’s Economic Role https://t.co/aMBZtn0gkM #Science #Business
    about 2 days ago
  • FDA expert panel gives thumbs-up to Aimmune’s peanut allergy drug https://t.co/srCucGLuB5
    about 3 days ago
  • A developer of a drug for migraine formulated as a dry powder and given as a nasal spray is raising $82.5 million i… https://t.co/gn4NSNTmBR
    about 3 days ago

Please share Science & Enterprise

Migraine Drug Developer Raises $82.5M in IPO

NASDAQ share price display

A developer of a drug for migraine formulated as a dry powder and given as a nasal spray is raising $82.5 million in its initial public offering of common stock. . . . → Read More: Migraine Drug Developer Raises $82.5M in IPO

A.I.-Powered Network to Identify, Build Molecules

Networked earth

A chemical engineering team is creating an open network for chemists and data scientists to share data for speeding the development of new molecules. . . . → Read More: A.I.-Powered Network to Identify, Build Molecules

NIH Funds Augmented-Reality Endovascular System

Heart, circulation system

A grant from National Institutes of Health is funding a system using augmented reality and holography to improve minimally-invasive repair of blood vessels. . . . → Read More: NIH Funds Augmented-Reality Endovascular System

Network to Promote Real-World Dementia Trials

Older couple

University and senior care center researchers are building a nationwide network to collect real-world evidence on caring for people with dementia. . . . → Read More: Network to Promote Real-World Dementia Trials

Gene-Editing Biotech Gains $34M in Early Funds

Sickle cell illustration

A two year-old enterprise spun-off from Yale University is developing gene-editing treatments for genetic disorders with synthetic peptides and DNA delivered in nanoscale particles. . . . → Read More: Gene-Editing Biotech Gains $34M in Early Funds

Sumitomo Dainippon, Biotechs in $3B Acquisition Deal

Laptops on a table

Japanese pharmaceutical company Sumitomo Dainippon agreed to acquire five biotechnology companies and gain an equity stake in the Roivant Sciences group. . . . → Read More: Sumitomo Dainippon, Biotechs in $3B Acquisition Deal

Gates Investing in HIV, Tuberculosis Immunotherapies

T-cell infected by HIV

The Bill and Melinda Gates Foundation is taking an equity stake in a biotechnology company developing immunotherapies from messenger RNA. . . . → Read More: Gates Investing in HIV, Tuberculosis Immunotherapies

Infographic – Biotech Index Falls in Summer

Nasdaq Biotech Index

It’s time to check in again on the NBI on its ups and downs since the start of 2019, our infographic for this weekend. . . . → Read More: Infographic – Biotech Index Falls in Summer

Math Model to Gauge Heart Attack Risk from Plaques

Heart, circulation system

An academic-industry collaboration is creating a non-invasive technique to detect rupture-prone plaque build-ups in arteries and predict one’s risk of heart attack. . . . → Read More: Math Model to Gauge Heart Attack Risk from Plaques

Small Biz Grant Funds Pre-Term Gut Microbe Therapy

Microbiome graphic

National Institutes of Health is supporting development of an extended-release probiotic treatment for necrotizing enterocolitis, an intestinal disease affecting premature infants. . . . → Read More: Small Biz Grant Funds Pre-Term Gut Microbe Therapy